Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

nordic pharma, s.r.o. - suhi ekstrakt lista čajevca, prečiščeni - mazilo - suhi ekstrakt lista čajevca, prečiščeni 100 mg / 1 g - sinekatehini

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

nordic pharma, s.r.o. - suhi ekstrakt lista čajevca, prečiščeni - mazilo - suhi ekstrakt lista čajevca, prečiščeni 100 mg / 1 g - sinekatehini

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmaswiss Česká republika s.r.o. - dokozanol - krema - dokozanol 100 mg / 1 g - dokozanol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmaswiss Česká republika s.r.o. - dokozanol - krema - dokozanol 100 mg / 1 g - dokozanol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - aciklovir - krema - aciklovir 50 mg / 1 g - aciklovir

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmaswiss Česká republika s.r.o. - dokozanol - krema - dokozanol 100 mg / 1 g - dokozanol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - aciklovir - krema - aciklovir 50 mg / 1 g - aciklovir

Evropska unija - slovenščina - EMA (European Medicines Agency)

viatris healthcare limited - imikvimod - keratosis; keratosis, actinic - antibiotiki in kemoterapevtiki za dermatološko uporabo - zyclara je indicirano za lokalno zdravljenje klinično značilno, -hyperkeratotic, -hipertrofična, vidne ali otipljiv aktinična keratoza poln obraz ali proćelav lasišča v imunokompetentni odrasli, ko so druge možnosti za lokalno zdravljenje kontraindiciran ali manj primerno.

Evropska unija - slovenščina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.